Cellectar Biosciences, a late-stage clinical biopharmaceutical company specializing in cancer drug development, has entered into an agreement with Evestia Clinical to provide full contract research organization (CRO) services for its upcoming Phase 1b study evaluating CLR 125 in the treatment of triple-negative breast cancer (TNBC). CLR 125 is an iodine-125 Auger-emitting drug candidate designed to target solid tumors, including triple-negative breast, lung, and colorectal cancers.
This new collaboration will capitalize on Evestia Clinical’s recently expanded global capabilities and oncology expertise, strengthened by its merger with Atlantic Research Group (ARG). Evestia brings extensive experience in oncology trials across both adult and pediatric populations, having participated in over 300 studies involving solid tumors and hematologic malignancies. The company also maintains partnerships with leading clinical sites, including the Mayo Clinic.
Jarrod Longcor, Chief Operating Officer at Cellectar, expressed confidence in Evestia’s tailored approach and combined expertise, stating that their partnership will be key to the success of the clinical trial. He also highlighted the company’s commitment to advancing CLR 125 as a promising new treatment option for patients with TNBC.
Paul Bishop, Chief Development Officer of Evestia, emphasized the long-standing relationship with Cellectar and the benefits of the recent merger, which has broadened their therapeutic expertise and enhanced their U.S. presence. He noted that these strengths will enable Evestia to deliver high-quality, customized services for complex oncology research.
In addition to the partnership with Evestia, Cellectar has selected a Mayo Clinic Network site as a treatment center for the Phase 1b trial. Dr. Pooja Advani from the Mayo Clinic will serve as the lead investigator, ensuring that patients receive care from clinicians with significant experience and expertise in oncology.
This collaboration marks a significant step forward for Cellectar as it advances CLR 125 through clinical development, aiming to provide new therapeutic options for patients with triple-negative breast cancer.